US FDA approves AstraZeneca’s immunotherapy for bladder cancer

Short resume:

astrazeneca
70%
approval
60%
investment
50%
therapeutics
50%

May 1 (Reuters) – The U.S. Food and Drug Administration on Monday granted accelerated approval to AstraZeneca Plc’s immuno-oncology drug to treat a type of bladder cancer in patients whose disease progressed despite chemotherapy.
Source Daily Mail
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*